Cargando…
The natural history of de novo donor-specific HLA antibodies after kidney transplantation
BACKGROUND: De novo donor-specific HLA antibodies (dnDSA) are key factors in the diagnosis of antibody-mediated rejection (ABMR) and related to graft loss. METHODS: This retrospective study was designed to evaluate the natural course of dnDSA in graft function and kidney allograft survival and to as...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523126/ https://www.ncbi.nlm.nih.gov/pubmed/36186822 http://dx.doi.org/10.3389/fmed.2022.943502 |
_version_ | 1784800202931044352 |
---|---|
author | López del Moral, Covadonga Wu, Kaiyin Naik, Marcel Osmanodja, Bilgin Akifova, Aylin Lachmann, Nils Stauch, Diana Hergovits, Sabine Choi, Mira Bachmann, Friederike Halleck, Fabian Schrezenmeier, Eva Schmidt, Danilo Budde, Klemens |
author_facet | López del Moral, Covadonga Wu, Kaiyin Naik, Marcel Osmanodja, Bilgin Akifova, Aylin Lachmann, Nils Stauch, Diana Hergovits, Sabine Choi, Mira Bachmann, Friederike Halleck, Fabian Schrezenmeier, Eva Schmidt, Danilo Budde, Klemens |
author_sort | López del Moral, Covadonga |
collection | PubMed |
description | BACKGROUND: De novo donor-specific HLA antibodies (dnDSA) are key factors in the diagnosis of antibody-mediated rejection (ABMR) and related to graft loss. METHODS: This retrospective study was designed to evaluate the natural course of dnDSA in graft function and kidney allograft survival and to assess the impact of mean fluorescence intensity (MFI) evolution as detected by annual Luminex(®) screening. All 400 kidney transplant recipients with 731 dnDSA against the last graft (01/03/2000-31/05/2021) were included. RESULTS: During 8.3 years of follow-up, ABMR occurred in 24.8% and graft loss in 33.3% of the cases, especially in patients with class I and II dnDSA, and those with multiple dnDSA. We observed frequent changes in MFI with 5-year allograft survivals post-dnDSA of 74.0% in patients with MFI reduction ≥ 50%, 62.4% with fluctuating MFI (MFI reduction ≥ 50% and doubling), and 52.7% with doubling MFI (log-rank p < 0.001). Interestingly, dnDSA in 168 (24.3%) cases became negative at some point during follow-up, and 38/400 (9.5%) patients became stable negative, which was associated with better graft survival. Multivariable analysis revealed the importance of MFI evolution and rejection, while class and number of dnDSA were not contributors in this model. CONCLUSION: In summary, we provide an in-depth analysis of the natural course of dnDSA after kidney transplantation, first evidence for the impact of MFI evolution on graft outcomes, and describe a relevant number of patients with a stable disappearance of dnDSA, related to better allograft survival. |
format | Online Article Text |
id | pubmed-9523126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95231262022-10-01 The natural history of de novo donor-specific HLA antibodies after kidney transplantation López del Moral, Covadonga Wu, Kaiyin Naik, Marcel Osmanodja, Bilgin Akifova, Aylin Lachmann, Nils Stauch, Diana Hergovits, Sabine Choi, Mira Bachmann, Friederike Halleck, Fabian Schrezenmeier, Eva Schmidt, Danilo Budde, Klemens Front Med (Lausanne) Medicine BACKGROUND: De novo donor-specific HLA antibodies (dnDSA) are key factors in the diagnosis of antibody-mediated rejection (ABMR) and related to graft loss. METHODS: This retrospective study was designed to evaluate the natural course of dnDSA in graft function and kidney allograft survival and to assess the impact of mean fluorescence intensity (MFI) evolution as detected by annual Luminex(®) screening. All 400 kidney transplant recipients with 731 dnDSA against the last graft (01/03/2000-31/05/2021) were included. RESULTS: During 8.3 years of follow-up, ABMR occurred in 24.8% and graft loss in 33.3% of the cases, especially in patients with class I and II dnDSA, and those with multiple dnDSA. We observed frequent changes in MFI with 5-year allograft survivals post-dnDSA of 74.0% in patients with MFI reduction ≥ 50%, 62.4% with fluctuating MFI (MFI reduction ≥ 50% and doubling), and 52.7% with doubling MFI (log-rank p < 0.001). Interestingly, dnDSA in 168 (24.3%) cases became negative at some point during follow-up, and 38/400 (9.5%) patients became stable negative, which was associated with better graft survival. Multivariable analysis revealed the importance of MFI evolution and rejection, while class and number of dnDSA were not contributors in this model. CONCLUSION: In summary, we provide an in-depth analysis of the natural course of dnDSA after kidney transplantation, first evidence for the impact of MFI evolution on graft outcomes, and describe a relevant number of patients with a stable disappearance of dnDSA, related to better allograft survival. Frontiers Media S.A. 2022-09-16 /pmc/articles/PMC9523126/ /pubmed/36186822 http://dx.doi.org/10.3389/fmed.2022.943502 Text en Copyright © 2022 López del Moral, Wu, Naik, Osmanodja, Akifova, Lachmann, Stauch, Hergovits, Choi, Bachmann, Halleck, Schrezenmeier, Schmidt and Budde. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine López del Moral, Covadonga Wu, Kaiyin Naik, Marcel Osmanodja, Bilgin Akifova, Aylin Lachmann, Nils Stauch, Diana Hergovits, Sabine Choi, Mira Bachmann, Friederike Halleck, Fabian Schrezenmeier, Eva Schmidt, Danilo Budde, Klemens The natural history of de novo donor-specific HLA antibodies after kidney transplantation |
title | The natural history of de novo donor-specific HLA antibodies after kidney transplantation |
title_full | The natural history of de novo donor-specific HLA antibodies after kidney transplantation |
title_fullStr | The natural history of de novo donor-specific HLA antibodies after kidney transplantation |
title_full_unstemmed | The natural history of de novo donor-specific HLA antibodies after kidney transplantation |
title_short | The natural history of de novo donor-specific HLA antibodies after kidney transplantation |
title_sort | natural history of de novo donor-specific hla antibodies after kidney transplantation |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523126/ https://www.ncbi.nlm.nih.gov/pubmed/36186822 http://dx.doi.org/10.3389/fmed.2022.943502 |
work_keys_str_mv | AT lopezdelmoralcovadonga thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT wukaiyin thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT naikmarcel thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT osmanodjabilgin thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT akifovaaylin thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT lachmannnils thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT stauchdiana thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT hergovitssabine thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT choimira thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT bachmannfriederike thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT halleckfabian thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT schrezenmeiereva thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT schmidtdanilo thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT buddeklemens thenaturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT lopezdelmoralcovadonga naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT wukaiyin naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT naikmarcel naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT osmanodjabilgin naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT akifovaaylin naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT lachmannnils naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT stauchdiana naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT hergovitssabine naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT choimira naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT bachmannfriederike naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT halleckfabian naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT schrezenmeiereva naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT schmidtdanilo naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation AT buddeklemens naturalhistoryofdenovodonorspecifichlaantibodiesafterkidneytransplantation |